Document Type
Article
Publication Date
6-10-2021
Publication Title
Scientific Reports
Abstract
The pro-homeostatic lipid mediators elovanoids (ELVs) attenuate cell binding and entrance of the SARS-CoV-2 receptor-binding domain (RBD) as well as of the SARS-CoV-2 virus in human primary alveoli cells in culture. We uncovered that very-long-chain polyunsaturated fatty acid precursors (VLC-PUFA, n-3) activate ELV biosynthesis in lung cells. Both ELVs and their precursors reduce the binding to RBD. ELVs downregulate angiotensin-converting enzyme 2 (ACE2) and enhance the expression of a set of protective proteins hindering cell surface virus binding and upregulating defensive proteins against lung damage. In addition, ELVs and their precursors decreased the signal of spike (S) protein found in SARS-CoV-2 infected cells, suggesting that the lipids curb viral infection. These findings open avenues for potential preventive and disease-modifiable therapeutic approaches for COVID-19.
First Page
1
Last Page
8
PubMed ID
34112906
Volume
11
Issue
1
Publisher
Nature Research
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Calandria, Jorgelina M.; Bhattacharjee, Surjyadipta; Maness, Nicholas J.; Kautzmann, Marie Audrey I.; Asatryan, Aram; Gordon, William C.; Do, Khanh V.; Jun, Bokkyoo; Mukherjee, Pranab K.; Petasis, Nicos A.; and Bazan, Nicolas G., "Elovanoids Downregulate SARS-CoV-2 Cell-Entry, Canonical Mediators and Enhance Protective Signaling in Human Alveolar Cells" (2021). School of Medicine Faculty Publications. 193.
https://digitalscholar.lsuhsc.edu/som_facpubs/193
File Format
File Size
2675 KB